Showing 1 - 20 results of 694 for search '(( significant adverse increase ) OR ( significant ((gap decrease) OR (a decrease)) ))', query time: 0.12s Refine Results
  1. 1

    The Impact of a Computerized Potassium Alert on Adverse Drug Events and Pharmacists' Interventions by Mansour, Hanine

    Published 2010
    “…Conclusions: Implementation of a computerized pharmacy alert resulted in a statistically significant decrease in adverse drug events related to hyperkalemia in our institution. …”
    Get full text
    Get full text
    Get full text
    Get full text
    article
  2. 2

    Oral contraceptive pills and possible adverse effects by Stone, Rebecca H

    Published 2014
    “…Oral contraceptive pills (OCPs) containing estrogen and progestin or progestin only were introduced as a contraceptive option for women in 1960. Since their introduction to the market, there have been significant changes in the drug content and formulations of these products, in part to decrease the risk of adverse effects. …”
    Get full text
    Get full text
    article
  3. 3

    A slow but steady nanoLuc: R162A mutation results in a decreased, but stable, nanoLuc activity by Wesam S. Ahmed (10170053)

    Published 2024
    “…Here, we combined molecular dynamics (MD) simulation and mutational analysis to show that the R162A mutation results in a decreased but stable <u>bioluminescence </u>activity of NLuc in living cells and in vitro. …”
  4. 4
  5. 5

    The Anti-Tumor Agent Sodium Selenate Decreases Methylated PP2A, Increases GSK3βY216 Phosphorylation, Including Tau Disease Epitopes and Reduces Neuronal Excitability in SHSY-5Y Neu... by Wesal Habbab (17346961)

    Published 2019
    “…Somewhat surprisingly, the catalytically active form, methylated PP2A (mePP2A) was significantly decreased. In close correlation to these data, the phosphorylation state of two substrate proteins, sensitive to PP2A activity, GSK3β and Tau were found to be increased. …”
  6. 6
  7. 7
  8. 8

    Prevalence, Associated Risk Factors, and Adverse Cardiovascular Outcomes of Statins Discontinuation: A Systematic Review by Shahd A. Ageeb (22047824)

    Published 2024
    “…Five studies that reported the cardiovascular risk of statin discontinuation within the first year of initiation showed significantly increased risk of discontinuation, including all‐cause mortality (hazard ratio: 1.36–3.65).…”
  9. 9
  10. 10

    Pravastatin plus L-arginine prevents adverse pregnancy outcomes in women with uteroplacental vascular dysfunction by Aleksandar Jurisic (17052408)

    Published 2021
    “…</p><h3>Objective</h3><p dir="ltr">The aim of this pilot non randomized control study was to use pravastatin +L-arginine to improve uteroplacental haemodynamics and prevent adverse maternal and neonatal outcomes in women with abnormal Dopplers and high risk for developing adverse pregnancy outcomes.…”
  11. 11
  12. 12

    Retrospective identification of medication related adverse events in the emergency medical services through the analysis of a patient safety register by Ian Howard (2026753)

    Published 2022
    “…Prehospital medication related adverse events remain a significant threat to patient safety in this setting and warrant greater widespread attention and future identification of strategies aimed at their reduction.…”
  13. 13

    Factors that influence patient and public adverse drug reaction reporting: a systematic review using the theoretical domains framework by Laila Shafei (17045772)

    Published 2023
    “…<h3>Background</h3><p dir="ltr">Only 5–10% of all adverse drug reactions (ADRs) are reported. Mechanisms to support patient and public reporting offer numerous advantages to health care systems including increasing reporting rate. …”
  14. 14

    Decreased Interfacial Dynamics Caused by the N501Y Mutation in the SARS-CoV-2 S1 Spike:ACE2 Complex by Wesam S. Ahmed (10170053)

    Published 2022
    “…<p dir="ltr">Coronavirus Disease of 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has resulted in a massive health crisis across the globe, with some genetic variants gaining enhanced infectivity and competitive fitness, and thus significantly aggravating the global health concern. …”
  15. 15

    Indomethacin as a Rescue Therapy for Patent Ductus Arteriosus in Extremely Premature Infants after Failed Ibuprofen Treatment by Amal Sabouni (17046236)

    Published 2023
    “…<p dir="ltr">Hemodynamically significant patent ductus arteriosus (hsPDA) is a major cause of neonatal morbidity and mortality in extremely low birth weight (ELBW) infants. …”
  16. 16

    Notch Signaling Inhibition by LY411575 Attenuates Osteoblast Differentiation and Decreased Ectopic Bone Formation Capacity of Human Skeletal (Mesenchymal) Stem Cells by Nihal AlMuraikhi (6002234)

    Published 2019
    “…Among the tested molecules, LY411575, a potent γ-secretase and Notch signaling inhibitor, exhibited significant inhibitory effects on osteoblastic differentiation of hBMSCs manifested by reduced ALP activity, mineralized matrix formation, and decreased osteoblast-specific gene expression as well as in vivo ectopic bone formation. …”
  17. 17
  18. 18

    Kefir exhibits anti‑proliferative and pro‑apoptotic effects on colon adenocarcinoma cells with no significant effects on cell migration and invasion by Khoury, Nathalie

    Published 2014
    “…Our data suggest that kefir is able to inhibit the proliferation and induce apoptosis in HT‑29 and Caco‑2 CRC cells, yet it does not exhibit a significant effect on the motility and invasion of these cells in vitro.…”
    Get full text
    Get full text
    Get full text
    article
  19. 19
  20. 20

    Evidence and gaps in clinical outcomes of novel pharmacologic therapies for sickle cell disease: A systematic literature review highlighting insights from clinical trials and real-... by Mohamed Yassin (4166515)

    Published 2025
    “…Real-world studies of crizanlizumab showed a reduction in complicated VOC events. The high discontinuation rate and results of the STAND trial led to a significant decrease in the use of crizanlizumab. …”